tiotropium respimat® improves physical functioning in chronic obstructive pulmonary disease

Clicks: 179
ID: 221133
2010
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #49 of 88 articles by views in tijdschrift voor geneeskunde

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Heike Rau-Berger1, Harald Mitfessel2, Thomas Glaab11Medical Affairs Germany, Respiratory Medicine, Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim; 2Pulmonology Practice, Remscheid, GermanyAim: This observational study with tiotropium Respimat® was performed in a real-life setting to investigate its effectiveness with regard to physical functioning and tolerability.Methods: Patients with chronic obstructive pulmonary disease (COPD; n = 1,230; mean age, 65.5 years) received tiotropium 5 µg once daily via Respimat® Soft Inhaler for 6 weeks in an open-label observational study. At baseline and week 6, patients completed the Physical Function subdomain [PF-10] of the Short Form (SF) 36 questionnaire.Results: Improvement in standardized PF-10 score of ≥10 points was achieved by 61.5% of patients. Mean (SD) standardized PF-10 scores improved by 13.4 (15.9) points, from 49.0 (24.5) to 62.3 points (23.5; P < 0.001). Results in smokers (n = 435) were not significantly different to those in nonsmokers. The general condition of patients improved during treatment. Adverse events were reported by 4.0% of patients and were chiefly respiratory symptoms and dry mouth.Conclusion: In COPD patients receiving tiotropium Respimat® in daily practice, physical function improved rapidly within 6 weeks of treatment, irrespective of smoking status.Keywords: COPD, tiotropium, physical function, therapy
Reference Key
rau-berger2010internationaltiotropium Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Heike Rau-Berger, Harald Mitfessel, Thomas Glaab
Are you one of these authors? Claim your profile
Journal tijdschrift voor geneeskunde
Year 2010
DOI
DOI not found
URL
http://www.dovepress.com/tiotropium-respimatreg-improves-physical-functioning-in-chronic-obstru-a5456
Keywords
diseases of the respiratory system

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.